tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Okyo Pharma initiated with a Buy at Lucid Capital

Lucid Capital analyst Elemer Piros initiated coverage of Okyo Pharma (OKYO) with a Buy rating and $13 price target The company is developing a drug for neuropathic corneal pain, an indication without an approved treatment, the analyst tells investors in a research note. The firm believes an efficacious treatment for an orphan eye indication, such as Oxervate for neurotrophic keratitis, can achieve blockbuster status.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1